View More View Less
  • 1 Országos Onkológiai Intézet, 1122 Budapest, Ráth György u. 7–9.
Restricted access

Az emlő karcinómája az egyik leggyakoribb női daganat. Ezek között a mintegy 15%-ban előforduló, sem ösztrogénreceptort, sem progeszteronreceptort nem expresszáló és HER2-pozitivitást sem mutató eseteket háromszorosan vagy tripla-negatív karcinómáknak (triple-negative breast cancer, TNBC) nevezzük. A betegség kedvezőtlen kórlefolyása, valamint elfogadott célzott kezelés hiánya az elmúlt években intenzív kutatás tárgyává tette e betegségcsoportot. A jelen tanulmányban a PubMed-ben 2007. januártól 2009. júniusig publikált közlemények között az emlődaganat és tripla-negatív kulcsszavakon túl, az epidemiológia, patológia, génprofil, prediktív, prognosztikus, terápia és összefoglaló kulcsszavakkal kikeresett közleményeket és a kapcsolódó releváns publikációk eredményeit foglaltuk össze. A TNBC esetén ismert tény, hogy fiatalabb életkorban jelentkezik és gyakoribb a szegényebb fekete vagy hispano-amerikai nőknél, az viszont újdonság, hogy kialakulásában szerepet játszhatnak hormonális tényezők és az elhízás is. A TNBC nem egységes betegség, mert mind hisztomorfológiailag, mind immunhisztokémiai vizsgálatokkal további alcsoportok különíthetőek el. A tripla-negatív tumorok között gyakrabban észlelhető örökletes BRCA1-mutáció vagy szerzett mutáció nélküli BRCA-diszfunkció. A nagyfokú hasonlóság miatt a korábbi években a tripla-negatív daganatokat sokan azonosították a génexpressziós profil alapján meghatározható ún. bazális-szerű tumorokkal, de ez a megfeleltetés ma már nem állja meg a helyét. Több nagy tanulmány igazolta, hogy a tripla-negativitás önmagában kedvezőtlen prognosztikus faktor, bár ismert, hogy a TNBC esetek kb. 10%-a kedvező prognózisú. Elfogadott célzott kezelés hiányában a szisztémás kezelés tekintetében csak a kemoterápia az, ami jelenleg rendelkezésre áll. A kísérleti fázisban lévő célzottan ható vegyületek közül a PARP1-inhibitorok érdemelnek különös figyelemet, mely vegyületek a DNS-javító apparátus hibás működését használják ki. Magyar Onkológia 54: 325–335, 2010

  • 1 Aksoy, S, Dizdar, O, Altundag, K et al. 2007 Demographic, clinical and pathological characteristics of Turkish triple-negative breast cancer patients: single center experience Ann Oncol 18 19041906.

    • Search Google Scholar
    • Export Citation
  • 2 Atchley, DP, Albarracin, CT, Lopez, A et al. 2008 Clinical and pathological characteristics of patients with BRCA-positive and BRCA-negative breast cancer J Clin Oncol 26 42824288.

    • Search Google Scholar
    • Export Citation
  • 3 Banerjee, S, Reis-Filho, JS, Ashley, S et al. 2006 Basal-like breast carcinomas: Clinical outcome and response to chemotherapy J Clin Pathol 59 729735.

    • Search Google Scholar
    • Export Citation
  • 4 Bauer, KR, Brown, M, Cress, RD et al. 2007 Descripitive analysis of estrogen receptor (ER)-negative, progesteron receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population based study from the California Cancer Registry Cancer 109 17211728.

    • Search Google Scholar
    • Export Citation
  • 5 Berry, DA, Cirrincione, C, Winer, EP 2006 Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer JAMA 295 16581667.

    • Search Google Scholar
    • Export Citation
  • 6 Bidard, FC, Conforti, R, André, F et al. 2007 Does triple-negative phenotype accurately identify basal-like tumor? An immunohistochemical analysis based on 143 ’triple-negative’ breast cancers Ann Oncol 18 12851286.

    • Search Google Scholar
    • Export Citation
  • 7 Bidard, FC, Matthieu, MC, Chollet, P et al. 2008 p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes Ann Oncol 19 12611265.

    • Search Google Scholar
    • Export Citation
  • 8 Brown, M, Tsodikov, A, Bauer, KR 2008 The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesteron receptor-negative, invasive breast cancer: the California Cancer Registry, 1999–2004 Cancer 112 737747.

    • Search Google Scholar
    • Export Citation
  • 9 Bryan, BB, Schnitt, SJ, Collins, LC 2006 Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer Mod Pathol 19 617621.

    • Search Google Scholar
    • Export Citation
  • 10 Bürger, H, Kersting, C, Hungermann, D et al. 2006 The significance of “normal tissue” in the development of breast cancer: new concepts of early carcinogenesis Pathologe 27 319325.

    • Search Google Scholar
    • Export Citation
  • 11 Byrski, T, Gronwald, J, Huzarski, T et al. 2008 Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers Breast Cancer Res Treat 108 289296.

    • Search Google Scholar
    • Export Citation
  • 12 Calza, S, Hall, P, Auer, G et al. 2006 Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients Breast Cancer Res 8 R34.

    • Search Google Scholar
    • Export Citation
  • 13 Carey, LA, Dees, EC, Perou, CM et al. 2007 The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 13 23292334.

    • Search Google Scholar
    • Export Citation
  • 14 Carey, LA, Mayer, E, Marcom, PK et al. 2007 TBCRC 001: EGFR inhibition with cetuximab in metastatic triple negative (basal-like) breast cancer Breast Cancer Res Treat 106 Suppl 1 S32.

    • Search Google Scholar
    • Export Citation
  • 15 Carey, LA, Perou, CM, Livasy, CA et al. 2008 Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study JAMA 295 2492502.

    • Search Google Scholar
    • Export Citation
  • 16 Chae, BJ, Bae, JS, Lee, A et al. 2009 p53 as a specific prognostic factor in triple-negative breast cancer Jpn J Clin Oncol 39 217224.

    • Search Google Scholar
    • Export Citation
  • 17 Cheang, MC, Voduc, D, Nielsen, TO et al. 2008 Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype Clin Cancer Res 14 13681376.

    • Search Google Scholar
    • Export Citation
  • 18 Chekhun, VF, Zhylchuk, VE, Lukyanova, NY et al. 2009 Expression of drug resistance proteins in triple-receptor-negative tumors as the basis of individualizied therapy of breast cancer patients Exp Oncol 31 123124.

    • Search Google Scholar
    • Export Citation
  • 19 Chiuri, VE, Leo, G, Lurosso, V 2007 Clinical and therapeutic perspectives of gene expression profiling for breast cancer Ann Oncol 18 Suppl 6 5862.

    • Search Google Scholar
    • Export Citation
  • 20 Cleator, S, Heller, W, Coomber, RC 2007 Triple-negative breast cancer: therapeutic options Lancet Oncol 8 235244.

  • 21 Colleoni, M, Viale, G, Zahrieh, D et al. 2008 Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy Ann Oncol 19 465472.

    • Search Google Scholar
    • Export Citation
  • 22 Collins, LC, Martyniak, AJ, Kandel, MJ et al. 2009 Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancer Am J Surg Pathol 33 10931097.

    • Search Google Scholar
    • Export Citation
  • 23 Dabbs, DJ, Chivukula, M, Carter, G et al. 2006 Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile Mod Pathol 19 15061511.

    • Search Google Scholar
    • Export Citation
  • 24 Dawood, S, Broglio, K, Gonzalez-Angulo, AM 2009 Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes J Clin Oncol 27 220226.

    • Search Google Scholar
    • Export Citation
  • 25 Giorgi De, U, Rosti, G, Frassineti, L et al. 2007 High-dose chemotherapy for triple negative breast cancer Ann Oncol 18 202203.

  • 26 Dent, R, Hanna, WM, Trudeau, M et al. 2008 Pattern of metastatic spread in triple-negative breast cancer Breast Cancer Res Treat 115 423428.

    • Search Google Scholar
    • Export Citation
  • 27 Dent, R, Trudeau, M, Pritchard, KI et al. 2007 Triple-negative breast cancer: clinical features and patterns of recurrence Clin Cancer Res 13 44294434.

    • Search Google Scholar
    • Export Citation
  • 28 Eralp, Y, Derin, D, Ozluk, Y et al. 2008 MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer Ann Oncol 19 669674.

    • Search Google Scholar
    • Export Citation
  • 29 Fan, C, Oh, DS, Wessels, L et al. 2006 Concordance among gene-expression based predictors for breast cancer N Eng J Med 355 560569.

  • 30 Frasci, G, Comella, P, Rinaldo, M et al. 2009 Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer Ann Oncol 20 11851192.

    • Search Google Scholar
    • Export Citation
  • 31 Freedman, GM, Anderson, PR, Li, T et al. 2009 Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation Cancer 115 946951.

    • Search Google Scholar
    • Export Citation
  • 32 Garber, JE, Richardson, A, Harris, LN et al. 2006 Neo-adjuvant cisplatin in triple-negative breast cancer Breast Cancer Res Treat 1000 S149.

    • Search Google Scholar
    • Export Citation
  • 33 Gluz, O, Nitz, UA, Harbeck, N et al. 2008 Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial Ann Oncol 19 861870.

    • Search Google Scholar
    • Export Citation
  • 34 Gronwald, J, Byrski, T, Huzarski, T et al. 2009 Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients J Clin Oncol 27 Suppl 15s.

    • Search Google Scholar
    • Export Citation
  • 35 Guarneri, V, Broglio, K, Gonzalez-Angulo, AM et al. 2006 Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors J Clin Oncol 24 10371044.

    • Search Google Scholar
    • Export Citation
  • 36 Halfty, BG, Yang, Q, Toppmeyer, D et al. 2006 Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer J Clin Oncol 24 5652.

    • Search Google Scholar
    • Export Citation
  • 37 Hanley, K, Wang, J, Bourne, P et al. 2008 Lack of expression of androgen receptor may play a clinical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast Hum Pathol 39 386392.

    • Search Google Scholar
    • Export Citation
  • 38 Hu, Z, Fan, C, Oh, DS et al. 2006 The molecular portraits of breast tumors are conserved across microarray platforms MBC Genomics 7 96.

  • 39 Ihemelandu, CU, Leffall, LD, Jr, Dewitty, RL et al. 2007 Molecular breast cancer subtypes in premenopausal and postmenopausal African-Amarican women: age-specific prevalence and survival J Surg Res 143 109118.

    • Search Google Scholar
    • Export Citation
  • 40 Ivanov, O, Chen, F, Wiley, EL et al. 2008 AlphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer Breast Cancer Res Treat 111 411417.

    • Search Google Scholar
    • Export Citation
  • 41 Iwase, H, Kurebayashi, J, Tsuda, H et al. 2010 Clinicopathological analysis of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society Breast Cancer 17 118124.

    • Search Google Scholar
    • Export Citation
  • 42 Jaspers, J, Rottenberg, S, Jonkers, J 2009 Therapeutic options for triple-negative breast cancers with defective homologous recombination Biochim Biophys Acta 1796 266280.

    • Search Google Scholar
    • Export Citation
  • 43 Kaufmann, M, Minckwitz von, G, Bear, HD et al. 2007 Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006 Ann Oncol 18 19271934.

    • Search Google Scholar
    • Export Citation
  • 44 Keam, B, Im, SA, Kim, HJ et al. 2007 Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer BMC Cancer 7 203.

    • Search Google Scholar
    • Export Citation
  • 45 Kim, MJ, Ro, JY, Ahn, SH et al. 2006 Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormon receptor and Her2/neu-overexpressing phenotypes Hum Pathol 37 12171226.

    • Search Google Scholar
    • Export Citation
  • 46 Kreike, B, Kouwenhove van, M, Vijver van de, MJ et al. 2007 Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas Breast Cancer Res 9 R65.

    • Search Google Scholar
    • Export Citation
  • 47 Kurebayashi, J 2009 Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics Breast Cancer 16 275280.

    • Search Google Scholar
    • Export Citation
  • 48 Kwan, ML, Kushi, LH, Weltzien, E et al. 2009 Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors Breast Cancer Res 11 R31.

    • Search Google Scholar
    • Export Citation
  • 49 Langerod, A, Zhao, H, Borgan, O et al. 2007 TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer Breast Cancer Res 9 R30.

    • Search Google Scholar
    • Export Citation
  • 50 Law, JH, Habibi, G, Hu, K et al. 2008 Phosphorylated insuline-like growth factor-I/insulin receptor is present in all breast cancer subtypes and is related to poor survival Cancer Res 68 1023810246.

    • Search Google Scholar
    • Export Citation
  • 51 Liedtke, C, Mazouni, C, Hess, KR et al. 2008 Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J Clin Oncol 26 12751281.

    • Search Google Scholar
    • Export Citation
  • 52 Liu, ZB, Liu, GY, Yang, WT et al. 2008 Triple-negative breast cancer types exhibit a distinct poor clinical characteristic in lymph node-negative Chinese patients Oncol Rep 20 987994.

    • Search Google Scholar
    • Export Citation
  • 53 Liu, ZB, Wu, J, Ping, B et al. 2009 Basal cytokeratin expression in relation to immonohistochemical and clinical characterization in breast cancer patients with triple negative phenotype Tumori 95 5362.

    • Search Google Scholar
    • Export Citation
  • 54 Mehta, RS 2008 Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: a step toward reversing triple-negative paradox J Clin Oncol 26 32863288.

    • Search Google Scholar
    • Export Citation
  • 55 Miyoshi, Y, Murase, K, Oh, K 2008 Basal-like subtype and BRCA1 dysfunction in breast cancer Int J Clin Oncol 13 395400.

  • 56 Moinfar, F 2008 Is “basal-like” carcinoma of the breast a distinct clinicopathological entity? A critical review with cautionary notes Pathobiology 75 119131.

    • Search Google Scholar
    • Export Citation
  • 57 Nahleh, Z 2010 Neoadjuvant chemotherapy for “triple negative” breast cancer: a review of current practice and future outlook Med Oncol 27 531539.

    • Search Google Scholar
    • Export Citation
  • 58 Nielsen, TO, Hsu, FD, Jensen, K et al. 2004 Immunhistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 10 53675374.

    • Search Google Scholar
    • Export Citation
  • 59 Nieto, Y, Shpall, EJ 2009 High-dose chemotherapy for high-risk primary and metastatic breast cancer: is another look warranted Curr Opin Oncol 21 150157.

    • Search Google Scholar
    • Export Citation
  • 60 Nishimura, R, Arima, N 2008 Is triple negative a prognostic factor in breast cancer? Breast Cancer 15 303308.

  • 61 O’Shaughnessy, J, Weckstein, DJ, Vukelja, SJ et al. 2007 Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer Breast Cancer Res Treat 106 Suppl 1 S32.

    • Search Google Scholar
    • Export Citation
  • 62 Ogawa, Y, Hai, E, Matsumoto, K et al. 2008 Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers Int J Clin Oncol 13 431435.

    • Search Google Scholar
    • Export Citation
  • 63 Onitilio, AA, Engel, JM, Greenlee, RT et al. 2009 Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival Clin Med Res 7 413.

    • Search Google Scholar
    • Export Citation
  • 64 Pal, SK, Mortimer, J 2009 Triple-negative breast cancer: Novel therapies and new directions Maturitas 63 269274.

  • 65 Perreard, L, Fan, C, Quackenbush, JF et al. 2006 Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay Breast Cancer Res 8 R23.

    • Search Google Scholar
    • Export Citation
  • 66 Phipps, AI, Malone, KE, Porter, PL et al. 2008 Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women Cancer Epidemiol Biomarkers Prev 17 20782086.

    • Search Google Scholar
    • Export Citation
  • 67 Pivot, XB, Li, RK, Thomas, ES et al. 2009 Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesteron receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer Eur J Cancer 45 29402946.

    • Search Google Scholar
    • Export Citation
  • 68 Potemski, P, Kusinska, R, Watala, C et al. 2005 Prognostic relevance of basal cytokeratin expression in operable breast cancer Oncology 69 478485.

    • Search Google Scholar
    • Export Citation
  • 69 Rakha, EA, Ellis, IO 2009 Triple-negative/basal-like breast cancer: review Pathology 41 4047.

  • 70 Rakha, EA, El-Sayed, ME, Green, AR et al. 2007 Prognostic markers in triple-negative breast cancer Cancer 109 2532.

  • 71 Rakha, EA, Reis-Filho, JS, Ellis, IO 2008 Basal-like breast cancer: A critical review J Clin Oncol 26 25682581.

  • 72 Reis-Filho, JS, Tutt, ANJ 2008 Triple negative tumours: a critical review Histopathology 52 108118.

  • 73 Rottenberg, S, Jaspers, JE, Kersbergen, A et al. 2008 High sensitivity of BRCA1-deficient mammary tumors to PARP inhibitor AZD228 alone and in combination with platinum drugs Proc Natl Acad Sci U S A 105 1707917084.

    • Search Google Scholar
    • Export Citation
  • 74 Rouzier, R, Perou, CM, Pusztai, L et al. 2005 Breast cancer molecular subtypes respond differently to preoperative chemotherapy Clin Cancer Res 11 56785685.

    • Search Google Scholar
    • Export Citation
  • 75 Sanchez-Munoz, A, Garcia-Tapiador, AM, Martinez-Ortega, E et al. 2008 Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer Clin Trans Oncol 10 646653.

    • Search Google Scholar
    • Export Citation
  • 76 Sekine, I, Shimizu, C, Nishio, K et al. 2009 A literature review of molecular markers predictive of clinical response of cytotoxic chemotherapy in patients with breast cancer Int J Clin Oncol 14 112119.

    • Search Google Scholar
    • Export Citation
  • 77 Sidoni, A, Cartaginese, F, Crinó, L et al. 2008 ERCC1 expression in triple negative breast carcinoma: the paradox revisited Breast Cancer Res Treat 111 569570.

    • Search Google Scholar
    • Export Citation
  • 78 Sirohi, B, Arnedos, M, Popat, S et al. 2008 Platinum-based chemotherapy in triple-negative breast cancer Ann Oncol 19 18471852.

  • 79 Soerjomataram, I, Louwman, MWJ, Ribot, JG et al. 2008 An overview of prognostic factors for long-term survivors of breast cancer Breast Cancer Res Treat 107 309330.

    • Search Google Scholar
    • Export Citation
  • 80 Solin, LJ, Hwang, WT, Vapiwala, N 2009 Outcome after breast conservation treatment with radiation for women with triple-negative early-stage invasive breast carcinoma Clin Breast Cancer 2 96100.

    • Search Google Scholar
    • Export Citation
  • 81 Sorlie, T, Perou, CM, Tibshirani, R et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implication Proc Natl Acad Sci U S A 98 1086910874.

    • Search Google Scholar
    • Export Citation
  • 82 Sorlie, T, Wang, Y, Xiao, C et al. 2006 Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analysis across three different platforms BMC Genomics 7 127.

    • Search Google Scholar
    • Export Citation
  • 83 Sotiriou, C, Neo, SY, McShane, LM et al. 2003 Breast cancer classification and prognosis based on gene expression profiles from a population-based study Proc Natl Acad Sci USA 100 1039310398.

    • Search Google Scholar
    • Export Citation
  • 84 Spitale, A, Mazzola, P, Soldini, D et al. 2009 Breast cancer classification according to immunohistochemical markers: clinicipathologic features and short-term survival analysis in a population-based study from the South of Switzerland Ann Oncol 20 628635.

    • Search Google Scholar
    • Export Citation
  • 85 Tan, DS, Marchio, C, Jones, RL et al. 2008 Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracyclin-treated patients Breast Cancer Res Treat 111 2744.

    • Search Google Scholar
    • Export Citation
  • 86 Tischkowitz, M, Brunet, JS, Begin, LR et al. 2007 Use of immunohistochemical markers can refine prognosis in triple negative breast cancer BMC Cancer 7 134.

    • Search Google Scholar
    • Export Citation
  • 87 Torrisi, R, Balduzzi, A, Ghisini, R et al. 2008 Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel Cancer Chemother Pharmacol 62 667672.

    • Search Google Scholar
    • Export Citation
  • 88 Toyama, T, Yamashita, H, Kondo, N et al. 2008 Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers BMC Cancer 8 309.

    • Search Google Scholar
    • Export Citation
  • 89 Trivers, KF, Lund, MJ, Porter, PL et al. 2009 The epidemiology of triple-negative breast cancer, including race Cancer Causes Control 20 10711082.

    • Search Google Scholar
    • Export Citation
  • 90 Turner, NC, Reis-Filho, JS, Russell, AM et al. 2007 BRCA1 dysfunction in sporadic basal-like breast cancer Oncogene 26 21262132.

  • 91 Tutt, A, Robson, M, Garber, JE et al. 2009 Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer J Clin Oncol (ASCO meeting abstracts) 27 CRA501.

    • Search Google Scholar
    • Export Citation
  • 92 Uhm, JE, Park, YH, Im, YH et al. 2009 Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy Int J Cancer 124 14571462.

    • Search Google Scholar
    • Export Citation
  • 93 Groep van der, P, Bouter, A, Zanden van der, R et al. 2006 Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data J Clin Pathol 59 611617.

    • Search Google Scholar
    • Export Citation
  • 94 Witkiewicz, AK, Dasgupta, A, Sotgia, F et al. 2009 An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers Am J Pathol 174 19961999.

    • Search Google Scholar
    • Export Citation
  • 95 Wysocki, PJ, Korski, K, Lamperska, K et al. 2008 Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations Med Sci Monit 14 SC710.

    • Search Google Scholar
    • Export Citation
  • 96 Yamamoto, Y, Ibusuki, M, Nakano, M et al. 2009 Clinical significance of basal-like subtype in triple-negative breast cancer Breast Cancer 16 260267.

    • Search Google Scholar
    • Export Citation